Fri Sep 20 09:14:50 UTC 2024: ## AnaptysBio CFO Sells $487,700 Worth of Stock
**SAN FRANCISCO, CA – September 20, 2024** – Dennis Mulroy, Chief Financial Officer of AnaptysBio, Inc. (NASDAQ: ANAB), sold 12,220 shares of the company’s stock on Monday, September 16th, according to a filing with the Securities and Exchange Commission (SEC). The shares were sold at an average price of $39.91, totaling $487,700.20. Following the transaction, Mulroy now owns 4,744 shares of AnaptysBio stock.
AnaptysBio, a clinical-stage biotechnology company, focuses on developing immunology therapeutics for various autoimmune and inflammatory diseases. The company’s recent quarterly earnings results, released on August 5th, showed a loss of $1.71 per share, missing analyst estimates. Revenue for the quarter reached $10.97 million, falling short of the predicted $25.85 million.
Several institutional investors have recently adjusted their positions in AnaptysBio. Fisher Asset Management LLC increased its stake by 0.7% in the fourth quarter, while Rhumbline Advisers and Algert Global LLC both boosted their holdings in the second quarter. Allspring Global Investments Holdings LLC made a new investment in the first quarter, and China Universal Asset Management Co. Ltd. expanded its stake in the same period.
Despite the recent decline in earnings and the CFO’s stock sale, AnaptysBio’s stock opened at $37.53 on Friday. The company’s market capitalization stands at $1.03 billion, with a PE ratio of -6.11 and a beta of -0.29. The stock’s 52-week low is $13.36, and its 52-week high is $41.31.
**Disclaimer:** This news article is based on publicly available information and should not be considered financial advice. Investors are advised to conduct their own research and consult with a financial professional before making any investment decisions.
First Piper 